Description
Background:
Abrilumab is a monoclonal antibody designed for the treatment of inflammatory bowel disease, ulcerative colitis, and Crohn’s disease. Abrilumab is a fully human monoclonal IgG2 directed against the human 47 integrin heterodimer. It specifically binds 47 with high affinity and inhibits alpha 4 beta 7, blocking its interaction with mucosal addressin cell adhesion molecule-1. Mucosal addressin cell adhesion molecule 1 is selectively expressed in gut endothelium and is upregulated in patients with IBD.
Intended Use:
For Estimation of Abrilumab in human serum and plasma. Please note the kit has not been optimized to be used for any other animal species. Should you require a specific sera tested, please connect with us at sales@krishgen.com for optimization.
Principle:
The method employs the quantitative sandwich enzyme immunoassay technique. Antibodies to Abrilumab are pre-coated onto microwells. Samples and standards are pipetted into microwells and human Abrilumab present in the sample are bound by the capture antibody. Then, a HRP (horseradish peroxidase) conjugated anti-Abrilumab antibody is pipetted and incubated. After washing microwells in order to remove any non-specific binding, the ready to use substrate solution (TMB) is added to microwells and color develops proportionally to the amount of Abrilumab in the sample. Color development is then stopped by addition of stop solution. Absorbance is measured at 450 nm.
If you have published a paper by using any of our ELISA since 01/01/2023, kindly fill out the “Krishgen Publication Reward Application Form” with complete information and send it by at email: info@krishgen.com, with the subject “Krishgen Publication Reward”. We will get back to you with the Amazon / Krishgen Credit Reward after we confirm it ASAP!